SG11201900501RA - Cannabis composition - Google Patents

Cannabis composition

Info

Publication number
SG11201900501RA
SG11201900501RA SG11201900501RA SG11201900501RA SG11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA
Authority
SG
Singapore
Prior art keywords
international
bay
western australia
perth
pct
Prior art date
Application number
SG11201900501RA
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65524553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201900501R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901222A external-priority patent/AU2017901222A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of SG11201900501RA publication Critical patent/SG11201900501RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Veh — 0—THC (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIPO I PCT mu °million °nolo ommillom noun° oimIE (10) International Publication Number WO 2018/023166 Al (51) International Patent Classification: A61K 31/352 (2006.01) A61K 36/00 (2006.01) A61K 31/05 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/AU2017/050817 (22) International Filing Date: 03 August 2017 (03.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/370,299 03 August 2016 (03.08.2016) US 2017901222 04 April 2017 (04.04.2017) AU 2017902065 31 May 2017 (31.05.2017) AU (71) Applicant: ZELDA THERAPEUTICS OPERATIONS PTY LTD [AU/AU]; Level 6, 105 St Georges Terrace, Perth, Western Australia 6000 (AU). (72) Inventors: KARELIS, Harry; Level 6, 105 St Georges Terrace, Perth, Western Australia 6000 (AU). GORDON, Mara; 3901 Bay Hill Rd, Bodega Bay, California 94923 (US). SMITH, Stewart; 3901 Bay Hill Rd, Bodega Bay, California 94923 (US). WASHER, Stewart; 6 Pemberton Close, Stirling, Western Australia 6021 (AU). (74) Agent: GRIFFITH HACK; Level 22, Allendale Square, 77 St Georges Terrace, Perth, Western Australia 6000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with amended claims (Art. 190)) = (54) Title: CANNABIS COMPOSITION Figure 1 1200.00 1000.00 800.00 600.00 400.00 200.00 0.00 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 Tu mor v o lu me (mm 3) Time (days) (57) : The invention relates to a method for treating cancer or a symptom associated with cancer. In particular, the present invention relates to a method for treating cancer or a symptom associated with cancer, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a Cannabis extract that comprises A 9 -tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition.
SG11201900501RA 2016-08-03 2017-08-03 Cannabis composition SG11201900501RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662370299P 2016-08-03 2016-08-03
AU2017901222A AU2017901222A0 (en) 2017-04-04 Cannabis composition
AU2017902065A AU2017902065A0 (en) 2017-05-31 Cannabis composition
PCT/AU2017/050817 WO2018023166A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
SG11201900501RA true SG11201900501RA (en) 2019-02-27

Family

ID=65524553

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900501RA SG11201900501RA (en) 2016-08-03 2017-08-03 Cannabis composition

Country Status (15)

Country Link
US (2) US11304925B1 (en)
EP (1) EP3493800A4 (en)
JP (2) JP2019526541A (en)
KR (3) KR20190034576A (en)
CN (1) CN109789123A (en)
AU (4) AU2017305103B2 (en)
BR (1) BR112019001794A2 (en)
CA (1) CA3031300A1 (en)
CL (1) CL2019000266A1 (en)
CO (1) CO2019001043A2 (en)
IL (1) IL264458B (en)
MX (1) MX2019001286A (en)
PE (2) PE20230607A1 (en)
SG (1) SG11201900501RA (en)
WO (1) WO2018023166A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190035791A (en) 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3103178A1 (en) * 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same
AU2018333282A1 (en) * 2017-09-15 2020-03-19 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US20230110830A1 (en) * 2018-04-09 2023-04-13 Ellevet Sciences Hemp extract for treatment of pain in animals
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
US11946016B2 (en) 2018-06-14 2024-04-02 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. Synthesis of cannabigerol
WO2020084423A1 (en) * 2018-10-24 2020-04-30 Radient Technologies Innovations Inc. Extraction-based contract execution
WO2020121312A1 (en) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
CA3154295A1 (en) * 2019-10-09 2021-04-15 Michael Foster DAVIS Aerosolisable material
EP4142929A4 (en) * 2020-04-29 2024-02-21 Ligar Lp Imprinted polymers and methods for their use
WO2021248207A1 (en) * 2020-06-12 2021-12-16 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
KR20220126653A (en) * 2021-03-08 2022-09-16 주식회사 엘지생활건강 The composition comprising cannabigerol
WO2022215071A1 (en) * 2021-04-05 2022-10-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Compositions and methods for the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (en) * 2000-10-17 2002-06-13 Adam Mueller Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2006063109A2 (en) * 2004-12-09 2006-06-15 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US20150126754A1 (en) * 2012-05-03 2015-05-07 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta-9-tetrahydrocannabinol and a method for preparing such an isolate
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
PT3062606T (en) 2013-10-29 2019-07-17 Biotech Inst Llc Breeding, production, processing and use of specialty cannabis
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
CA3111682A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
AU2015308546A1 (en) 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
CA2965493C (en) 2014-10-21 2021-12-07 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
AU2015360349B2 (en) 2014-12-12 2020-10-08 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
WO2016105514A1 (en) * 2014-12-23 2016-06-30 Biotech Institute, Llc A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
US10406186B2 (en) * 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
KR20190035791A (en) 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 Cannabis composition
SG11201900596XA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition

Also Published As

Publication number Publication date
KR102447510B1 (en) 2022-09-27
EP3493800A4 (en) 2020-04-08
US11304925B1 (en) 2022-04-19
CA3031300A1 (en) 2018-02-08
US20220202767A1 (en) 2022-06-30
JP7139559B2 (en) 2022-09-21
PE20230607A1 (en) 2023-04-13
IL264458B (en) 2021-06-30
AU2019203529A1 (en) 2019-06-06
AU2021205115B2 (en) 2023-06-15
BR112019001794A2 (en) 2019-05-07
AU2021205115A1 (en) 2021-08-12
CO2019001043A2 (en) 2020-06-19
MX2019001286A (en) 2019-06-13
AU2017305103B2 (en) 2019-02-21
AU2017305103A1 (en) 2018-07-05
AU2019203529B2 (en) 2021-04-29
JP2019526541A (en) 2019-09-19
KR20190034576A (en) 2019-04-02
EP3493800A1 (en) 2019-06-12
CL2019000266A1 (en) 2019-10-04
NZ750272A (en) 2021-09-24
KR20220132674A (en) 2022-09-30
PE20200677A1 (en) 2020-06-11
JP2021054836A (en) 2021-04-08
IL264458A (en) 2019-02-28
AU2018100920B4 (en) 2019-02-07
CN109789123A (en) 2019-05-21
KR20210129747A (en) 2021-10-28
AU2018100920A4 (en) 2018-08-02
WO2018023166A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
SG11201900501RA (en) Cannabis composition
SG11201900596XA (en) Cannabis composition
SG11201900665VA (en) Cannabis composition
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201909837YA (en) Methods for treating lung disorders
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901172QA (en) A method for manufacturing a fuel component
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate